Ukwehla Kwesisindo Okuphezulu ku-Tirzepatide Izixhumanisi Ezicini Eziyisikhombisa

Phakathi kwabantu abangama-3188 abanesifo sikashukela sohlobo 2 ababebambelele kuhlobo lwabo lwe-tirzepatide (Mounjaro, Lilly) ezivivinyweni ezine ezibalulekile ze-ejenti, ingxenye yesine yazuza okungenani ukusikwa ngo-15% esisindweni sabo sokuqala ngemuva kwamaviki angama-40-42 okwelashwa, futhi abacwaningi bathola okuguquguqukayo okuyisikhombisa okuyisisekelo okwakuxhunyaniswe kakhulu nesigameko esiphezulu saleli zinga lokulahlekelwa kwesisindo.

"Lokhu okutholakele kusiza ukwazisa ukuthi yibaphi abantu abanesifo sikashukela sohlobo lwe-2 okungenzeka ukuthi bathole ukuncipha okukhulu kwesisindo somzimba ngezici ezithuthukisiwe zengozi ye-cardiometabolic nge-tirzepatide," kusho ababhali.

INDLELA YOKWENZIWA:

• Abaphenyi benze ukuhlaziya kwe-post hoc kwedatha eqoqwe kubantu abangu-3188 abanesifo sikashukela sohlobo 2 ababebambelele kuhlobo lwe-tirzepatide ababelwenzile amasonto angama-40-42 kunoma yiluphi olunye lwezivivinyo ezine ezibalulekile ze-ejenti: SURPASS-1, SURPASS- 2, SURPASS-3, kanye ne-SURPASS-4.
• Abacwaningi babehlose ukukhomba izibikezelo zokuncipha kwesisindo somzimba okungenani esingu-15% ngokwelashwa kwe-tirzepatide kunoma yimiphi imithamo emithathu ehloliwe ― 5 mg, 10 mg, noma 15 mg ― eyayilawulwa ngomjovo ongaphansi kwesikhumba kanye ngesonto.
• Zonke izivivinyo ezine ezinikeze idatha zinqatshelwe ukwelashwa ngesikhathi esisodwa okuzokhuthaza ukwehla kwesisindo, futhi abantu abafakwe ekuhlaziyeni abazange bathole noma yimiphi imithi yokuhlenga yokulawula i-glycemia.
• Isilinganiso esiyinhloko sokusebenza ngempumelelo kuzo zonke izifundo ezine kwakuyikhono le-tirzepatide lokuthuthukisa ukulawulwa kwe-glycemic (okukalwa ngele-A1c) uma kuqhathaniswa ne-placebo, semaglutide (Ozempic) 1 mg SC kanye ngesonto, insulin degludec (Tresiba, Novo Nordisk), noma insulin glargine ( Basaglar, Lilly).

UKUDLA OKUDLELA ENDLINI:

• Phakathi kwabantu abangu-3188 abahlala bebambelele ohlelweni lwabo lwe-tirzepatide amasonto angu-40-42, i-792 (25%) ithole ukuncipha kwesisindo okungenani ngo-15% kusukela ekuqaleni.
• Ukuhlaziywa kwe-multivariate kwama-covariate ayisisekelo kubonise ukuthi lezi zici eziyisikhombisa zazihlotshaniswa kakhulu no-≥15% ukuncipha kwesisindo: umthamo ophezulu we-tirzepatide, ukuba ngowesifazane, ukuba ngowohlanga oluMhlophe noma lwase-Asia, ukuba mdala ngeminyaka, ukwelashwa nge-metformin, nokulawulwa okungcono kwe-glycemic. nge-A1c ephansi kanye ne-glucose yokuzila ukudla ephansi), kanye nezinga eliphansi le-non-high-density lipoprotein cholesterol.
• Ngesikhathi sokulandelela, ukufinyelelwa kokusika okungenani okungu-15% kwesisindo somzimba esiyisisekelo kwahlotshaniswa ngokuphawulekayo nokuncipha okukhulu kwe-A1c, izinga le-glucose yokuzila ukudla, umjikelezo okhalweni, umfutho wegazi, izinga le-serum triglyceride, nezinga le-serum le-enzyme yesibindi i-alanine transaminase. .
  

  IYAKWENZA:

  "Lokhu okutholakele kungase kunikeze ulwazi olubalulekile kubahlengikazi nakubantu abanesifo sikashukela sohlobo 2 mayelana nethuba lokuthola ukunciphisa okukhulu kwesisindo somzimba nge-tirzepatide, futhi kusize ukukhomba ukuthuthuka okungenzeka kubonakale ezinhlobonhlobo zemingcele engozini ye-cardiometabolic ngokuncipha kwesisindo okubangelwa i-tirzepatide. ,” kuphetha ababhali embikweni wabo.